--- canonical_name: Sh-Polypeptide-9 alternate_names: CG-VEGF, rh-Polypeptide-9, Recombinant Human Vascular Endothelial Growth Factor A, sh-Polypeptide 9 canonical_topic: Sh-Polypeptide-9 for Hair Regrowth short_topic_lc: sh_polypeptide_9_hair creation_date: 2026-0628-0004 creator_ai_fullname: Opus 4.8 --- # Sh-Polypeptide-9 for Hair Regrowth
Evidence Review created on 06/28/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** CG-VEGF, rh-Polypeptide-9, Recombinant Human Vascular Endothelial Growth Factor A, sh-Polypeptide 9 ## Motivation Sh-Polypeptide-9 is a lab-made copy of one of the body's main blood-vessel-growth signals — the molecule that tells the body to build new blood vessels. It is added to topical scalp serums and to injectable "hair cocktails" with the idea that better blood supply to the hair root can wake up sluggish follicles and support regrowth. Because hair follicles need a rich blood supply during their growth phase, boosting this signal at the scalp is an appealing target for people troubled by thinning hair. The idea grew out of basic biology showing that follicles with more surrounding blood vessels grow larger, thicker hairs, and that blocking this growth signal shrinks them. This led cosmetic chemists to package a look-alike of the signal into scalp products, often alongside copper peptides and other growth factors, and it now appears in several premium hair lines and clinic injection blends. This review examines what is actually known about Sh-Polypeptide-9 for hair regrowth: the laboratory and human evidence, how it is thought to work, its expected benefits and risks, how it is used in practice, and where the science is still thin. It separates what has been tested from what remains theoretical. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level expert and academic resources that discuss Sh-Polypeptide-9 or peptides based on VEGF (vascular endothelial growth factor, the body's main signal for growing new blood vessels) for hair growth in substantial depth. * [sh-Polypeptide-9 – Vascular Endothelial Growth Factor A (VEGFA)](https://ci.guide/peptides/sh-polypeptide-9) - Ghochikyan A physician-authored cosmetic-ingredient monograph that describes what Sh-Polypeptide-9 is, its proposed mechanism in restoring scalp microcirculation, and its comparison to minoxidil in laboratory work. It is the single most focused overview of the ingredient itself. * [Blueprint Haircare Stack: Product Review](https://perfecthairhealth.com/blueprint-haircare-stack-product-review/) - Williams A critical, evidence-focused review on Rob English's hair-science platform of a commercial peptide serum containing Sh-Polypeptide-9, examining how much of its formula is supported by human data versus marketing claims. * [Peptides and Hair Growth: Scientific Mechanisms, Clinical Evidence, and Practical Applications in Modern Trichology](https://trichology.com/trichologyjournal/peptides-for-hair-growth/) - Sarmiento, 2025 A trichology-focused overview placing VEGF-mimetic and copper peptides in the broader landscape of peptide hair therapies, useful for understanding where Sh-Polypeptide-9 sits among alternatives and how strong the supporting evidence is. * [The human tri-peptide GHK and tissue remodeling](https://pubmed.ncbi.nlm.nih.gov/18644225/) - Pickart, 2008 A foundational narrative review by the discoverer of the copper-peptide field, explaining how peptides that raise VEGF and other growth factors increase hair follicle size, providing the mechanistic backdrop for VEGF-mimetic hair peptides. * [Control of hair growth and follicle size by VEGF-mediated angiogenesis](https://pubmed.ncbi.nlm.nih.gov/11181640/) - Yano et al., 2001 The landmark primary study showing that increasing VEGF enlarges hair follicles and accelerates regrowth while blocking it does the opposite — the core biological rationale on which Sh-Polypeptide-9 rests. _Note: No content from the prioritized experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension) addressing Sh-Polypeptide-9 or VEGF-peptide hair products could be located despite both web and on-site searches; the list above is therefore drawn from the next-most-relevant expert and academic sources._ ## Grokipedia No Grokipedia article exists for Sh-Polypeptide-9. ## Examine No Examine article exists for Sh-Polypeptide-9. Examine.com focuses on orally ingested dietary supplements and does not cover topical or injectable cosmetic peptides such as this one. ## ConsumerLab No ConsumerLab article exists for Sh-Polypeptide-9. ConsumerLab tests orally ingested supplements for purity and does not cover topical cosmetic peptides. ## Systematic Reviews No systematic reviews or meta-analyses for Sh-Polypeptide-9 were found on PubMed as of 28 June 2026. ## Mechanism of Action Sh-Polypeptide-9 is a biotechnology-produced analog of human VEGF-A (vascular endothelial growth factor A, the body's master signal for growing new blood vessels). Its proposed action on hair rests on the well-established link between follicle blood supply and hair growth. * **Perifollicular angiogenesis (growth of blood vessels around the follicle):** During the active growth phase of a hair (anagen), the follicle is wrapped in an expanding network of tiny blood vessels that deliver oxygen and nutrients to the rapidly dividing hair-matrix cells. VEGF is the principal driver of this vessel growth. Animal work showed that raising VEGF enlarges follicles and produces thicker hairs, while neutralizing VEGF shrinks them — establishing vascular supply as a rate-limiting factor for follicle size. * **Dermal papilla signaling:** The dermal papilla is the cluster of cells at the follicle base that orchestrates the hair cycle. In laboratory coculture of human dermal papilla cells with microvascular endothelial cells, Sh-Polypeptide-9 increased cell proliferation and modulated signaling molecules (including β-catenin, a hub of the Wnt pathway that promotes the growth phase, and a reduction in the inflammatory signal IL-1α). This suggests the peptide may act not only on vessels but on the follicle's own control center. * **Comparison with minoxidil:** Minoxidil, the most studied topical hair drug, is itself thought to work partly by upregulating VEGF. Laboratory comparisons reported that encapsulated Sh-Polypeptide-9 raised VEGF, basic fibroblast growth factor (bFGF, another growth signal), and β-catenin, and offered some protection against oxidative stress — overlapping with minoxidil's proposed pathway but via direct VEGF mimicry rather than indirect induction. Competing interpretation: critics note that topically applied VEGF-mimetic peptides are large molecules that penetrate intact skin poorly, so a key open question is whether enough reaches the dermal papilla to reproduce the effects seen when the peptide is added directly to cells in a dish. Formulators address this with encapsulation or by injecting the peptide, but the penetration question remains a genuine point of mechanistic debate. As a peptide rather than a small-molecule drug, Sh-Polypeptide-9 does not have a conventional oral pharmacology profile (half-life, CYP metabolism). Native VEGF-A has a short circulating half-life (on the order of tens of minutes) and is broken down by general proteases; it acts locally at the VEGFR-2 receptor (the main VEGF docking site on blood-vessel cells) rather than being distributed and metabolized like an ingested drug. ## Historical Context & Evolution * **Original purpose of VEGF biology:** VEGF was first characterized in the context of blood-vessel growth, wound healing, and tumor biology. Its central role in hair was uncovered around 2001, when transgenic and antibody experiments in mice demonstrated that VEGF-driven blood-vessel growth controls follicle size — research that reframed scalp blood supply as a lever for hair growth. * **Translation into cosmetics:** Because recombinant human VEGF protein is expensive and unstable, cosmetic developers turned to engineered VEGF analogs and "biomimetic peptides" that imitate growth-factor signaling. Sh-Polypeptide-9 (also marketed as CG-VEGF) emerged as one such ingredient, given an International Nomenclature of Cosmetic Ingredients (INCI) name and incorporated into topical serums and clinic injection blends, frequently paired with copper tripeptide-1 and other growth factors. * **What the early research actually showed:** The first dedicated follicle study (a 2016 coculture letter) reported that Sh-Polypeptide-9 increased proliferation of human dermal papilla and endothelial cells and shifted signaling toward the growth phase. This was promising in-vitro evidence but did not, by itself, demonstrate regrowth on a human scalp. * **Evolving opinion:** Enthusiasm for VEGF-mimetic hair peptides remains tempered. The biological rationale is robust and the laboratory signals are consistent, yet rigorous human trials of Sh-Polypeptide-9 as an isolated ingredient have not been performed. Newer human studies test it only inside multi-ingredient cosmetic blends, so its independent contribution is still unresolved rather than settled in either direction. ## Expected Benefits Benefits are framed for proactive, risk-aware adults considering Sh-Polypeptide-9 as part of a hair-optimization regimen. A central caveat applies throughout: nearly all human evidence comes from multi-ingredient blends, so benefits attributable to Sh-Polypeptide-9 alone are difficult to isolate. ### Medium 🟩 🟩 #### Increased Perifollicular Blood Supply (Anagen Support) The strongest and most consistent rationale is that Sh-Polypeptide-9, as a VEGF mimic, promotes growth of the small blood vessels surrounding the follicle, which in turn supports the active growth phase and larger follicle size. This is grounded in landmark animal work showing VEGF directly controls follicle size, plus human cell-culture data showing the peptide raises proliferation and pro-growth signaling in dermal papilla and endothelial cells. The evidence basis is strong mechanistically but indirect for finished-product scalp outcomes. **Magnitude:** In animal models, VEGF overexpression increased follicle size and hair-shaft diameter by roughly 25–70%; no equivalent isolated human figure exists for the peptide. ### Low 🟩 #### Reduced Hair Shedding and Increased Density Within Peptide Blends ⚠️ Conflicted When Sh-Polypeptide-9 is included in PRP-like (platelet-rich plasma-like) cosmetic peptide solutions, randomized and pilot human studies report meaningful regrowth and reduced shedding. A randomized controlled trial in alopecia areata using a biomimetic-peptide cosmetic (containing Sh-Polypeptide-9 among others) reported about 57% mean scalp regrowth at three months versus about 28% with placebo; this trial was run by the industry-linked International Hair Research Foundation, a conflict of interest to weigh when reading the result. The conflict is twofold: the effect cannot be attributed to Sh-Polypeptide-9 specifically rather than the copper peptide or other growth factors in the blend, and alopecia areata (an autoimmune patchy hair loss) responds to many interventions including placebo, so generalization to common pattern hair loss is uncertain. **Magnitude:** Blend studies report roughly 57–68% regrowth in alopecia areata and an 83% reduction in hair-pull-test positivity in an injectable growth-factor pilot; the isolated contribution of Sh-Polypeptide-9 is unquantified. #### Thicker Terminal Hair and Improved Graft Survival A first-in-man injectable growth-factor formulation (including a copper tripeptide and VEGF) reported a shift from fine vellus hairs toward thicker terminal hairs and increased shaft diameter, and a separate study used a biomimetic peptide solution as a storage medium that improved hair-follicle graft survival during transplantation. These point to a plausible follicle-strengthening and tissue-supportive effect consistent with the VEGF mechanism, though again within combination products. **Magnitude:** Increased terminal-hair counts and shaft diameter reported qualitatively; a one-year total-hair-count increase reached statistical significance (P = 0.002) in the injectable pilot, but not isolated to Sh-Polypeptide-9. ### Speculative 🟨 #### Antioxidant and Anti-Inflammatory Scalp Support Laboratory observations suggest Sh-Polypeptide-9 may reduce the inflammatory signal IL-1α (a known inhibitor of hair growth) and protect scalp cells from oxidative stress. If real on the human scalp, this could create a more favorable micro-environment for follicles, but the basis is cell-culture and mechanistic only, with no controlled human data isolating this effect. #### Synergy With Minoxidil-Like Pathways Because both minoxidil and Sh-Polypeptide-9 are thought to raise VEGF, the peptide is sometimes proposed as a complement or alternative to minoxidil for people who cannot tolerate it. This is mechanistically reasonable and supported by laboratory comparisons, but no head-to-head human trial has tested whether Sh-Polypeptide-9 matches or adds to minoxidil's regrowth. ## Benefit-Modifying Factors * **Genetic polymorphisms:** No genetic variants have been established that modify the benefit of Sh-Polypeptide-9; as a topical/injectable peptide it is not subject to the drug-metabolizing enzyme variation relevant to oral drugs, and no VEGF-pathway polymorphism has been validated as a predictor of response. * **Baseline scalp vascular and follicle status:** Individuals with miniaturizing-but-living follicles and reduced perifollicular blood flow have the most theoretical room to benefit from a VEGF-driven approach; scarring alopecia with destroyed follicles would not be expected to respond. * **Type of hair loss:** The human blend evidence is strongest in alopecia areata (autoimmune patchy loss). Benefit in common androgenetic (pattern) hair loss is extrapolated and unproven, because pattern loss is hormone-driven and a vascular signal alone may be insufficient. * **Delivery method and penetration:** Because the peptide is a large molecule, benefit is highly dependent on formulation. Encapsulated topicals or intradermal injection are expected to outperform simple aqueous serums that may not reach the dermal papilla. * **Baseline biomarker levels:** There is no validated blood biomarker that predicts response; scalp VEGF status is not routinely measurable, so baseline biomarkers are not currently a practical guide to benefit for this peptide. * **Sex-based differences:** No reliable sex-specific efficacy data exist for Sh-Polypeptide-9; the injectable growth-factor pilot included both male and female pattern loss and reported benefit in both, but did not isolate this ingredient or formally compare sexes. * **Age-related considerations:** Older adults at the upper end of the target range tend to have more advanced follicle miniaturization and reduced dermal vascularity, which may blunt response; conversely, earlier-stage loss with viable follicles is more likely to respond. No age-stratified data are available. ## Potential Risks & Side Effects Risks are framed for proactive adults; the overall safety signal in published cosmetic and pilot studies is favorable, but data are limited and almost always from blended products. ### Low 🟥 #### Local Application and Injection-Site Reactions Topical scalp peptide products and intradermal growth-factor injections can cause transient redness, itching, stinging, or mild irritation at the application or injection site. Injectable use additionally carries the generic risks of needling — bruising, brief tenderness, and a small infection risk. In the published human pilot and RCT data, treatments were generally well tolerated with no serious adverse events, and reactions were mild and self-limited. **Magnitude:** Mild, transient local reactions; in the injectable growth-factor pilot of 1,000 patients, treatment was reported as well tolerated with no serious adverse events. ### Speculative 🟨 #### Theoretical Concern in VEGF-Sensitive Conditions (Psoriasis, Active Skin Cancer) Because VEGF drives blood-vessel and tissue growth, ingredient guidance recommends that people with psoriasis (where excess VEGF activity contributes to plaques) avoid Sh-Polypeptide-9 products, and that they not be used on sunburned skin or after high-dose ultraviolet exposure. By extension, a theoretical concern exists about applying a vessel-growth signal over skin with active or suspected skin cancer, since tumors exploit angiogenesis. These cautions are mechanistic and precautionary; no human cases of harm from cosmetic Sh-Polypeptide-9 have been documented. #### Uncertain Long-Term Local Effects of Repeated VEGF Signaling Sustained, repeated stimulation of an angiogenic signal in the scalp has not been studied for long-term safety. Whether chronic use could produce unwanted changes in scalp vasculature or skin is unknown, with no controlled long-term data; the basis for flagging it is biological plausibility and the absence of long-duration trials. #### Allergic or Hypersensitivity Reactions to Formulation Components As with any topical or injectable cosmetic containing peptides, preservatives, and carriers, allergic contact dermatitis or hypersensitivity is possible in susceptible individuals. Reports are isolated and not specific to Sh-Polypeptide-9, so this is flagged as speculative. ## Risk-Modifying Factors * **Genetic polymorphisms:** No pharmacogenetic variants are known to modify the risk profile of Sh-Polypeptide-9; as a topical/injectable peptide it is not subject to the liver-enzyme variation relevant to oral drugs. * **Baseline biomarker levels:** No blood biomarker predicts adverse response. People with conditions of dysregulated angiogenesis (e.g., active proliferative retinopathy) have no validated marker to guide safety here, but the underlying condition itself is the relevant flag. * **Sex-based differences:** No sex-specific differences in side effects have been established for this peptide. * **Pre-existing health conditions:** Psoriasis, active or recently treated skin cancer of the scalp, and other VEGF-driven dermatologic conditions raise the theoretical risk and are the main reasons to avoid use; recent sunburn or high UV exposure to the scalp is a temporary contraindication per ingredient guidance. * **Age-related considerations:** Older adults more commonly have actinic (sun-damaged) scalp skin and a higher background risk of scalp skin cancers, which is relevant to the precautionary VEGF cautions; no age-specific toxicity data exist. ## Key Interactions & Contraindications * **Prescription drug interactions:** No formal drug-interaction studies exist for Sh-Polypeptide-9. A theoretical pharmacodynamic interaction exists with systemic anti-angiogenic cancer drugs (VEGF inhibitors such as bevacizumab, or tyrosine-kinase inhibitors like sunitinib and pazopanib), where a topical VEGF-mimetic could in principle act opposite to therapy; relevance to scalp-applied cosmetic doses is unestablished. Severity: caution. * **Over-the-counter medication interactions:** No established interactions with OTC oral medications. Topically, concurrent use of strong scalp irritants or exfoliating acids could increase local irritation. Severity: caution. * **Supplement interactions:** No documented systemic supplement interactions. * **Supplements/agents with additive effects:** Other VEGF-raising or angiogenic hair actives — copper peptides (copper tripeptide-1 / GHK-Cu), procyanidins, and topical minoxidil — may have additive pro-angiogenic effects when layered, which is generally the intended pairing in commercial formulations rather than a hazard. Severity: monitor (for cumulative irritation). * **Other intervention interactions:** Frequently combined with microneedling or intradermal injection to improve delivery; combining with these increases penetration and therefore both potential benefit and local reaction. * **Populations who should avoid it:** People with psoriasis, active or suspected scalp skin cancer, sunburned scalp skin, and those on systemic anti-VEGF cancer therapy should avoid use. Pregnant and breastfeeding individuals should avoid it given the absence of safety data. * **Severity and consequence detail:** The psoriasis caution is treated as a relative-to-absolute contraindication (consequence: potential disease aggravation via excess VEGF activity); active scalp malignancy is an absolute contraindication (consequence: theoretical tumor angiogenesis support). * **Mitigating actions:** Where caution applies, separating application from irritant scalp products, patch-testing before full use, and avoiding application to broken or sunburned skin reduce risk. * **Population thresholds:** Avoid in psoriasis with active scalp plaques, any active scalp non-melanoma or melanoma skin cancer, scalp sunburn within the preceding days, and during pregnancy or lactation. ## Risk Mitigation Strategies * **Patch test before first scalp use:** Apply a small amount to a discreet area of skin and wait 24–48 hours to check for redness or itching, mitigating allergic contact dermatitis and hypersensitivity reactions before full-scalp exposure. * **Avoid compromised or sun-exposed scalp skin:** Do not apply to sunburned, broken, or recently high-UV-exposed scalp, mitigating the precautionary VEGF-over-damaged-skin concern flagged in ingredient guidance. * **Screen for VEGF-sensitive conditions first:** Confirm absence of active psoriasis and active or suspected scalp skin cancer before starting, mitigating the theoretical risk of aggravating angiogenesis-driven disease. * **Use validated, encapsulated, or clinic-administered formulations:** Choosing professionally formulated encapsulated topicals or clinician-delivered injections rather than ad-hoc raw-peptide mixtures mitigates both contamination/infection risk and the unpredictability of poorly absorbed product. * **Separate from irritant scalp actives:** Apply at a different time from exfoliating acids, retinoids, or other strong scalp irritants — for example several hours apart — to mitigate cumulative local irritation. * **Maintain aseptic technique for injectable use:** If used as an intradermal injection, ensuring sterile technique and trained administration mitigates injection-site infection, bruising, and bleeding. ## Therapeutic Protocol There is no standardized, evidence-validated protocol for Sh-Polypeptide-9 as an isolated intervention; the following reflects how it appears in practice within products and clinic regimens. * **Topical serum use (most common):** Marketed in leave-on scalp serums applied once or twice daily to the affected scalp, typically as part of a multi-peptide formula. Leading cosmetic formulators emphasize encapsulation to aid penetration. * **Intradermal injection ("hair cocktail"):** In clinic settings the peptide appears in injectable growth-factor blends delivered into the scalp roughly every 2–3 weeks for a course of several sessions (the published growth-factor pilot used eight sessions every three weeks), often by dermatologists or facial-plastic clinicians who popularized these formulations. * **Competing approaches:** A conventional approach favors established drugs (topical minoxidil, oral finasteride) as first line, positioning peptides as adjuncts; an integrative/cosmetic approach uses peptide blends and PRP-like cosmetics as a stand-alone or combination option. Neither is framed here as the default; the peptide's independent efficacy versus these is unproven. * **Best time of day:** No circadian timing advantage is established; topical products are generally applied to a clean, dry scalp, and consistency matters more than time of day. * **Half-life consideration:** As a VEGF-mimetic peptide, it acts locally and is broken down by tissue proteases over a short period (native VEGF half-life is on the order of tens of minutes), which is the rationale for repeated daily topical application or spaced repeat injections rather than single dosing. * **Single versus split dosing:** Practical regimens favor repeated low-dose exposure (daily topical, or repeated injection sessions) over a single application, consistent with the peptide's short local persistence. * **Genetic polymorphisms:** No pharmacogenetic variant is known to guide dosing for this peptide. * **Sex-based differences:** No validated sex-based dosing differences; mixed-sex pilot data did not define separate protocols. * **Age-related considerations:** Older adults with advanced miniaturization may require combination with established therapies for any meaningful effect; no age-specific dose is defined. * **Baseline biomarker levels:** No baseline lab value guides dosing. * **Pre-existing health conditions:** Protocol should be withheld in the contraindicated conditions (psoriasis, active scalp malignancy, sunburned scalp, pregnancy/lactation) rather than dose-adjusted. ## Discontinuation & Cycling * **Lifelong versus short-term:** Like other non-curative hair actives, any benefit is expected to depend on continued use; the underlying drivers of hair loss are unaddressed, so stopping is likely to allow gradual reversion. This is inferred from the broader hair-active literature, not from dedicated discontinuation studies of Sh-Polypeptide-9. * **Withdrawal effects:** No specific withdrawal syndrome is documented; unlike the well-known temporary shedding seen when stopping some drugs, no such effect has been characterized for this peptide. * **Tapering-off protocol:** No tapering is required for a topical cosmetic peptide; it can be stopped abruptly, with the expectation that any gains fade over subsequent hair cycles. * **Cycling:** No evidence supports or refutes cycling for maintained efficacy; there is no established cycling protocol, and continuous use is the implicit model in product instructions. ## Sourcing and Quality * **Identity and labeling:** Look for the INCI name "sh-Polypeptide-9" (or the synonym CG-VEGF) on the ingredient list, with a clearly stated concentration where possible; reputable brands disclose that the peptide is recombinant/biotechnologically produced. * **Formulation and delivery:** Prefer products that specify a penetration-enhancing system (e.g., liposomal or double-layer encapsulation), since an unencapsulated large peptide in a simple aqueous serum is unlikely to reach the dermal papilla. * **Purity and third-party testing:** Because this is a cosmetic peptide rather than a regulated drug, choose manufacturers that provide certificates of analysis or third-party testing for identity, purity, and microbial contamination; raw "research peptide" powders of uncertain origin carry contamination and mislabeling risk. * **Reputable sources:** Established cosmeceutical brands and licensed compounding or aesthetic clinics that source from recognized peptide suppliers are preferable to unverified online resellers of bulk peptide. * **Storage:** Peptide products are typically sensitive to heat and light; follow refrigeration or cool-storage instructions to preserve activity, as degraded peptide loses any potential benefit. ## Practical Considerations * **Time to effect:** Hair interventions act over hair-cycle timescales; in the blended human studies, regrowth was assessed at three to four months, and any topical effect would similarly be judged over a minimum of three to six months rather than weeks. * **Common pitfalls:** Expecting drug-level results from a cosmetic peptide; using a poorly absorbed simple serum; attributing the regrowth seen in multi-ingredient blends to Sh-Polypeptide-9 alone; and substituting it for proven therapies in significant pattern hair loss. * **Regulatory status:** Sh-Polypeptide-9 is regulated as a cosmetic ingredient (INCI-listed), not as an approved drug for hair loss; injectable growth-factor use is generally off-label/clinic-based and not approved as a standardized treatment. It has not received drug approval for androgenetic alopecia. * **Cost and accessibility:** Premium peptide serums and clinic injection courses can be expensive relative to generic minoxidil or finasteride, and clinician-administered injectable blends are the more costly and less accessible route. * **Overall framing:** Best understood as an adjunctive, mechanistically promising but clinically unproven option rather than a stand-alone treatment. ## Interaction with Foundational Habits * **Sleep:** Direction — none established. There is no known mechanism by which a topically applied scalp VEGF-mimetic peptide affects sleep, and no data suggest sleep disruption or improvement; practical consideration: none specific. * **Nutrition:** Direction — indirect, potentiating. Adequate protein, iron, zinc, and overall nutritional status are upstream requirements for hair growth, so correcting deficiencies plausibly enables any peptide benefit to manifest; the peptide itself does not deplete nutrients. Practical consideration: ensure iron and protein sufficiency before expecting topical results. * **Exercise:** Direction — indirect, potentiating. Exercise improves systemic and cutaneous blood flow, which is mechanistically aligned with the peptide's vascular target, though no study has tested an exercise–peptide interaction; practical consideration: none specific beyond general cardiovascular health. * **Stress management:** Direction — indirect. Psychological stress can trigger or worsen hair shedding (and alopecia areata in particular), so stress reduction may improve the background condition the peptide is applied to; the peptide has no known direct effect on cortisol or the stress response. ## Monitoring Protocol & Defining Success Because Sh-Polypeptide-9 is a topical/injectable cosmetic without systemic absorption concerns, monitoring is primarily clinical and photographic rather than laboratory-based. Before starting, a baseline assessment of hair status and a screen for contraindicating skin conditions is appropriate; ongoing monitoring tracks regrowth over hair-cycle timeframes. Baseline assessment should be performed before the first application: standardized scalp photographs, a hair-pull test, and (where available) trichoscopy or hair-count measurement, plus a skin examination to exclude psoriasis or scalp skin cancer. Ongoing monitoring follows a cadence of reassessment at roughly 3 months, 6 months, and then every 6 months, since meaningful change cannot be judged sooner than one full hair cycle. The lab table below lists optional bloodwork relevant not to the peptide itself but to ruling out common, treatable contributors to hair loss that would otherwise limit any response. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --------- | ------------------------ | --------------- | ------------- | | Ferritin (iron stores) | 50–100+ ng/mL | Low iron stores are a common, correctable cause of hair shedding | Conventional "normal" starts ~15–30 ng/mL, well below the functional hair threshold; fasting not required, but avoid testing during active infection (falsely raised) | | TSH | 1.0–2.0 mIU/L | Thyroid dysfunction causes diffuse hair loss that mimics or compounds other causes | TSH (thyroid-stimulating hormone); best drawn in the morning, fasting; pair with free T4 if abnormal | | Vitamin D (25-OH) | 40–60 ng/mL | Low vitamin D is associated with hair-cycle disturbance and alopecia areata | No fasting needed; interpret alongside season and supplementation | | Zinc | 90–120 µg/dL | Zinc deficiency impairs hair-follicle function and protein synthesis | Draw fasting in the morning; avoid zinc supplements for several hours beforehand to avoid falsely high readings | * **Functional vs. conventional ranges:** The ferritin target reflects functional-medicine guidance for hair (50–100+ ng/mL) rather than the much lower conventional deficiency cutoff; this distinction is the main reason "normal" labs can still coincide with shedding. Qualitative markers to track alongside labs and photographs: * Subjective reduction in daily hair shedding (e.g., hairs on pillow, in shower drain). * Visible new short regrowth or "baby hairs" along thinning areas or the hairline. * Improvement in hair-pull test (fewer hairs extracted). * Perceived increase in overall density, coverage, or hair-shaft thickness. ## Emerging Research * **No isolated-ingredient trials registered:** A ClinicalTrials.gov search returned no registered trials of Sh-Polypeptide-9 (or CG-VEGF) as a stand-alone hair intervention, which is the central gap: until such a trial exists, its independent efficacy cannot be confirmed. * **Human blend studies as the current frontier:** The most relevant recent human work tests Sh-Polypeptide-9 inside multi-peptide cosmetics — a randomized controlled trial in alopecia areata ([Rinaldi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30513014/)) and a study using a biomimetic peptide solution as graft-storage and donor-scalp media in transplantation ([Gold et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40228316/)). Both carry a conflict of interest: the first comes from the industry-linked International Hair Research Foundation, and the second evaluates a named commercial cocktail (QR678 Neo®) whose makers have a direct financial stake in a favorable result. Future work isolating the peptide would strengthen the case; null results in such designs would weaken it. * **Foundational mechanistic work continues:** Research into VEGF-driven follicle angiogenesis ([Colin-Pierre et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34957110/)) and the dermal-papilla coculture model first applied to this peptide ([Bassino et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26662923/)) continues to clarify whether boosting VEGF signaling translates to durable human regrowth. * **Delivery innovation:** A recurring theme is improving scalp penetration of large peptides — work on ionic-liquid microemulsions and encapsulation for topical peptide delivery ([Liu et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38026438/)) could determine whether topical Sh-Polypeptide-9 can reach its target in humans, a prerequisite for any non-injected benefit. * **Direction that could weaken the case:** Evidence that VEGF blockade in skin-organ models harms dermal vasculature ([Luengas-Martinez et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32570235/)) underscores VEGF's importance but also flags that the therapeutic window and long-term safety of chronically stimulating scalp angiogenesis remain unstudied; rigorous safety data could either reassure or temper enthusiasm. ## Conclusion Sh-Polypeptide-9 is a lab-made copy of the body's main blood-vessel-growth signal, added to scalp serums and clinic injection blends with the goal of feeding hair roots and waking up sluggish follicles. The biology behind it is sound: follicles need a rich blood supply to grow thick hairs, and raising this signal enlarges follicles in animals and stirs growth activity in human cells grown in the lab. That makes it a mechanistically appealing option for people actively working to keep or regrow hair. The catch is that almost all of the human testing has been done with mixtures that combine this peptide with copper peptides and other growth factors, so it is impossible to say how much of the reported regrowth comes from Sh-Polypeptide-9 itself. Much of that testing also comes from companies and groups that sell or profit from these products, a conflict of interest that weakens how far the findings can be trusted. There are no studies of it on its own, and a real open question is whether enough of this large molecule even reaches the hair root through intact skin. Side effects in the published studies were mild, mostly local irritation, though people with psoriasis or active scalp skin problems are advised to avoid it. Overall, the evidence is early and indirect. It is best viewed as a promising but unproven add-on rather than a stand-alone answer, with the strongest, most established hair options lying elsewhere. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**